The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

Chad A. Dickey, Adeela Kamal, Karen Lundgren, Natalia Klosak, Rachel M. Bailey, Judith Dunmore, Peter Ash, Sareh Shoraka, Jelena Zlatkovic, Christopher B. Eckman, Cam Patterson, Dennis W. Dickson, N. Stanley Nahman, Michael Hutton, Francis Burrows, Leonard Petrucelli

Research output: Contribution to journalArticle

424 Citations (Scopus)

Abstract

A primary pathologic component of Alzheimer's disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau). Expediting the removal of these p-tau species may be a relevant therapeutic strategy. Here we report that inhibition of Hsp90 led to decreases in p-tau levels independent of heat shock factor 1 (HSF1) activation. A critical mediator of this mechanism was carboxy terminus of Hsp70-interacting protein (CHIP), a tau ubiquitin ligase. Cochaperones were also involved in Hsp90-mediated removal of p-tau, while those of the mature Hsp90 refolding complex prevented this effect. This is the first demonstration to our knowledge that blockade of the refolding pathway promotes p-tau turnover through degradation. We also show that peripheral administration of a novel Hsp90 inhibitor promoted selective decreases in p-tau species in a mouse model of tauopathy, further suggesting a central role for the Hsp90 complex in the pathogenesis of tauopathies. When taken in the context of known high-affinity Hsp90 complexes in affected regions of the AD brain, these data implicate a central role for Hsp90 in the development of AD and other tauopathies and may provide a rationale for the development of novel Hsp90-based therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)648-658
Number of pages11
JournalJournal of Clinical Investigation
Volume117
Issue number3
DOIs
StatePublished - Mar 1 2007

Fingerprint

Tauopathies
tau Proteins
Alzheimer Disease
Neurofibrillary Tangles
Proteins
Ligases
Ubiquitin
Shock
Hot Temperature
Brain
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., ... Petrucelli, L. (2007). The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. Journal of Clinical Investigation, 117(3), 648-658. https://doi.org/10.1172/JCI29715

The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. / Dickey, Chad A.; Kamal, Adeela; Lundgren, Karen; Klosak, Natalia; Bailey, Rachel M.; Dunmore, Judith; Ash, Peter; Shoraka, Sareh; Zlatkovic, Jelena; Eckman, Christopher B.; Patterson, Cam; Dickson, Dennis W.; Nahman, N. Stanley; Hutton, Michael; Burrows, Francis; Petrucelli, Leonard.

In: Journal of Clinical Investigation, Vol. 117, No. 3, 01.03.2007, p. 648-658.

Research output: Contribution to journalArticle

Dickey, CA, Kamal, A, Lundgren, K, Klosak, N, Bailey, RM, Dunmore, J, Ash, P, Shoraka, S, Zlatkovic, J, Eckman, CB, Patterson, C, Dickson, DW, Nahman, NS, Hutton, M, Burrows, F & Petrucelli, L 2007, 'The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins', Journal of Clinical Investigation, vol. 117, no. 3, pp. 648-658. https://doi.org/10.1172/JCI29715
Dickey, Chad A. ; Kamal, Adeela ; Lundgren, Karen ; Klosak, Natalia ; Bailey, Rachel M. ; Dunmore, Judith ; Ash, Peter ; Shoraka, Sareh ; Zlatkovic, Jelena ; Eckman, Christopher B. ; Patterson, Cam ; Dickson, Dennis W. ; Nahman, N. Stanley ; Hutton, Michael ; Burrows, Francis ; Petrucelli, Leonard. / The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 3. pp. 648-658.
@article{2ace70f35a9740ae8953c21ac60c046a,
title = "The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins",
abstract = "A primary pathologic component of Alzheimer's disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau). Expediting the removal of these p-tau species may be a relevant therapeutic strategy. Here we report that inhibition of Hsp90 led to decreases in p-tau levels independent of heat shock factor 1 (HSF1) activation. A critical mediator of this mechanism was carboxy terminus of Hsp70-interacting protein (CHIP), a tau ubiquitin ligase. Cochaperones were also involved in Hsp90-mediated removal of p-tau, while those of the mature Hsp90 refolding complex prevented this effect. This is the first demonstration to our knowledge that blockade of the refolding pathway promotes p-tau turnover through degradation. We also show that peripheral administration of a novel Hsp90 inhibitor promoted selective decreases in p-tau species in a mouse model of tauopathy, further suggesting a central role for the Hsp90 complex in the pathogenesis of tauopathies. When taken in the context of known high-affinity Hsp90 complexes in affected regions of the AD brain, these data implicate a central role for Hsp90 in the development of AD and other tauopathies and may provide a rationale for the development of novel Hsp90-based therapeutic strategies.",
author = "Dickey, {Chad A.} and Adeela Kamal and Karen Lundgren and Natalia Klosak and Bailey, {Rachel M.} and Judith Dunmore and Peter Ash and Sareh Shoraka and Jelena Zlatkovic and Eckman, {Christopher B.} and Cam Patterson and Dickson, {Dennis W.} and Nahman, {N. Stanley} and Michael Hutton and Francis Burrows and Leonard Petrucelli",
year = "2007",
month = "3",
day = "1",
doi = "10.1172/JCI29715",
language = "English (US)",
volume = "117",
pages = "648--658",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

AU - Dickey, Chad A.

AU - Kamal, Adeela

AU - Lundgren, Karen

AU - Klosak, Natalia

AU - Bailey, Rachel M.

AU - Dunmore, Judith

AU - Ash, Peter

AU - Shoraka, Sareh

AU - Zlatkovic, Jelena

AU - Eckman, Christopher B.

AU - Patterson, Cam

AU - Dickson, Dennis W.

AU - Nahman, N. Stanley

AU - Hutton, Michael

AU - Burrows, Francis

AU - Petrucelli, Leonard

PY - 2007/3/1

Y1 - 2007/3/1

N2 - A primary pathologic component of Alzheimer's disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau). Expediting the removal of these p-tau species may be a relevant therapeutic strategy. Here we report that inhibition of Hsp90 led to decreases in p-tau levels independent of heat shock factor 1 (HSF1) activation. A critical mediator of this mechanism was carboxy terminus of Hsp70-interacting protein (CHIP), a tau ubiquitin ligase. Cochaperones were also involved in Hsp90-mediated removal of p-tau, while those of the mature Hsp90 refolding complex prevented this effect. This is the first demonstration to our knowledge that blockade of the refolding pathway promotes p-tau turnover through degradation. We also show that peripheral administration of a novel Hsp90 inhibitor promoted selective decreases in p-tau species in a mouse model of tauopathy, further suggesting a central role for the Hsp90 complex in the pathogenesis of tauopathies. When taken in the context of known high-affinity Hsp90 complexes in affected regions of the AD brain, these data implicate a central role for Hsp90 in the development of AD and other tauopathies and may provide a rationale for the development of novel Hsp90-based therapeutic strategies.

AB - A primary pathologic component of Alzheimer's disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau). Expediting the removal of these p-tau species may be a relevant therapeutic strategy. Here we report that inhibition of Hsp90 led to decreases in p-tau levels independent of heat shock factor 1 (HSF1) activation. A critical mediator of this mechanism was carboxy terminus of Hsp70-interacting protein (CHIP), a tau ubiquitin ligase. Cochaperones were also involved in Hsp90-mediated removal of p-tau, while those of the mature Hsp90 refolding complex prevented this effect. This is the first demonstration to our knowledge that blockade of the refolding pathway promotes p-tau turnover through degradation. We also show that peripheral administration of a novel Hsp90 inhibitor promoted selective decreases in p-tau species in a mouse model of tauopathy, further suggesting a central role for the Hsp90 complex in the pathogenesis of tauopathies. When taken in the context of known high-affinity Hsp90 complexes in affected regions of the AD brain, these data implicate a central role for Hsp90 in the development of AD and other tauopathies and may provide a rationale for the development of novel Hsp90-based therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=33847369469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847369469&partnerID=8YFLogxK

U2 - 10.1172/JCI29715

DO - 10.1172/JCI29715

M3 - Article

C2 - 17304350

AN - SCOPUS:33847369469

VL - 117

SP - 648

EP - 658

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -